Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:7474 |
Name | malignant pleural mesothelioma |
Definition | A pleural cancer that has_material_basis_in mesothelium cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer pleural cancer malignant pleural mesothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA R88Q | Apitolisib | malignant pleural mesothelioma | predicted - sensitive | detail... |
ALK rearrange | Conteltinib | malignant pleural mesothelioma | no benefit | detail... |
EML4 - ALK | Alectinib | malignant pleural mesothelioma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Alectinib | malignant pleural mesothelioma | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Lorlatinib | malignant pleural mesothelioma | predicted - sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M ALK G1202R | Lorlatinib | malignant pleural mesothelioma | predicted - resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00996385 | Phase II | Bortezomib + Oxaliplatin | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | Unknown status | USA | 0 |
NCT01064648 | Phase Ib/II | Cediranib + Cisplatin + Pemetrexed Disodium | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
NCT01265433 | Phase II | Montanide ISA 51 + Sargramostim Montanide ISA 51 + Sargramostim + WT1 vaccine | WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | Completed | USA | 0 |
NCT01769547 | Phase II | Dovitinib | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy | Terminated | CAN | 0 |
NCT01868022 | Phase I | Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel | Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Completed | USA | NLD | GBR | ESP | DNK | BEL | 1 |
NCT01870609 | Phase II | Defactinib | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | Terminated | USA | SWE | POL | NZL | NOR | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 2 |
NCT01907100 | Phase III | Cisplatin + Pemetrexed Disodium Nintedanib | Nintedanib (BIBF 1120) in Mesothelioma | Terminated | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | HRV | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT02004028 | Phase II | Defactinib | Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. | Terminated | USA | 0 |
NCT02399371 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT02414269 | Phase I | Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | Active, not recruiting | USA | 0 |
NCT02568449 | Phase II | Nintedanib | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | Completed | USA | 0 |
NCT02592551 | Phase II | Durvalumab + Tremelimumab Durvalumab | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | Completed | USA | 0 |
NCT02639091 | Phase I | Anetumab ravtansine + Cisplatin + Pemetrexed Disodium | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | Completed | USA | ITA | 0 |
NCT02707666 | Phase I | Pembrolizumab Cisplatin + Pemetrexed Disodium | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | Terminated | USA | 0 |
NCT02709512 | Phase II | Cisplatin + Pemetrexed Disodium ADI-PEG 20 + Cisplatin + Pemetrexed Disodium | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC) | Completed | USA | ITA | GBR | AUS | 1 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02784171 | Phase II | Cisplatin + Pemetrexed Disodium Pembrolizumab | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | Active, not recruiting | ITA | FRA | CAN | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02863055 | Phase II | Nintedanib | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO) | Active, not recruiting | ITA | GBR | BEL | 0 |
NCT02899195 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) | Completed | USA | 0 |
NCT02899299 | Phase III | Carboplatin + Cisplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Completed | USA | TUR | ROU | POL | NLD | ITA | GRC | GBR | FRA | DEU | CHE | BRA | BEL | AUS | 7 |
NCT02959463 | Phase I | Pembrolizumab | Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Completed | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03075527 | Phase II | Durvalumab + Tremelimumab | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | Suspended | USA | 0 |
NCT03126630 | Phase Ib/II | Pembrolizumab Anetumab ravtansine + Pembrolizumab | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Active, not recruiting | USA | CAN | 0 |
NCT03175172 | Phase II | CRS-207 + Pembrolizumab | Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM | Terminated | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03228537 | Phase I | Atezolizumab + Cisplatin + Pemetrexed Disodium | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT03319537 | Phase Ib/II | MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Terminated | USA | 0 |
NCT03399552 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | Completed | USA | 0 |
NCT03546426 | Phase I | Aldesleukin + Pembrolizumab | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX) | Active, not recruiting | ITA | 0 |
NCT03644550 | Phase II | LMB-100 + Pembrolizumab | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | Terminated | USA | 0 |
NCT03710876 | Phase III | Celecoxib + Gemcitabine Celecoxib + Gemcitabine + Nadofaragene firadenovec | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE) | Active, not recruiting | USA | POL | ITA | GBR | FRA | DEU | CAN | AUS | 1 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03760575 | Phase I | Cisplatin + Pembrolizumab + Pemetrexed Disodium | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) | Recruiting | USA | 0 |
NCT03762018 | Phase III | Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (BEAT-meso) | Active, not recruiting | ITA | GBR | FRA | ESP | CHE | BEL | 0 |
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03918252 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Active, not recruiting | USA | 0 |
NCT03920839 | Phase I | Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Withdrawn | 0 | |
NCT04013334 | Phase II | MTG201 + Nivolumab | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | Unknown status | USA | 0 |
NCT04040231 | Phase I | Galinpepimut-S + Nivolumab + Sargramostim | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | Active, not recruiting | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04162015 | Phase I | Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | Active, not recruiting | USA | 0 |
NCT04166734 | Phase I | Pembrolizumab | Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME) | Terminated | GBR | 0 |
NCT04177953 | Phase II | Carboplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery | Active, not recruiting | DEU | 0 |
NCT04201145 | Phase I | Pembrolizumab Defactinib + Pembrolizumab | Pembrolizumab + Defactinib In Pleural Mesothelioma | Withdrawn | USA | 0 |
NCT04287829 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA) | Active, not recruiting | NLD | 0 |
NCT04300244 | Phase II | Ipilimumab + Nivolumab + UV1 Telomerase peptide vaccine Ipilimumab + Nivolumab | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) | Active, not recruiting | SWE | NOR | ESP | DNK | AUS | 0 |
NCT04334759 | Phase III | Durvalumab Cisplatin + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) | Active, not recruiting | USA | NZL | AUS | 0 |
NCT04400539 | Phase II | Nivolumab | The IMmunotherapy Pleural 5-ALA PDT (IMPALA) | Recruiting | FRA | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04525859 | Phase I | Poly ICLC | Poly-ICLC (Hiltonol) Vaccine In Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
NCT04577326 | Phase I | ATA2271 Cyclophosphamide | Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | Active, not recruiting | USA | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04840615 | Phase I | Ipilimumab + LMB-100 | Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | Terminated | USA | 0 |
NCT04857372 | Phase I | IAG933 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 1 |
NCT04897022 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | Recruiting | USA | 0 |
NCT04914897 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 Pembrolizumab + THOR-707 Nab-paclitaxel + Pembrolizumab + THOR-707 Cisplatin + Pembrolizumab + Pemetrexed Disodium + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | Terminated | USA | POL | ITA | FRA | ESP | AUS | ARG | 4 |
NCT04940637 | Phase II | Dostarlimab-gxly + Niraparib | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001) | Recruiting | ITA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04996017 | Phase III | Atezolizumab | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso) | Unknown status | ITA | 0 |
NCT05005429 | Phase II | Bintrafusp alfa | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES) | Completed | ESP | 0 |
NCT05071014 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Cryoablation in People With Mesothelioma | Completed | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | AUS | 0 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05375825 | Phase I | LMB-100 | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin | Withdrawn | USA | 0 |
NCT05425576 | Phase II | Pembrolizumab + Trabedersen | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | Not yet recruiting | USA | 0 |
NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Recruiting | AUS | 1 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |
NCT05647265 | Phase II | Ipilimumab + Nivolumab | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | Recruiting | USA | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05765084 | Phase Ib/II | Atezolizumab + Cisplatin + Pemetrexed Disodium + WT1 mRNA-electroporated DC vaccine | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma (Immuno-MESODEC) | Recruiting | BEL | 0 |
NCT05795595 | Phase Ib/II | CTX131 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05932199 | Phase Ib/II | Durvalumab + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT06097728 | Phase III | Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + MEDI5752 + Pemetrexed Disodium Ipilimumab + Nivolumab | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso) | Recruiting | USA | TUR | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | 5 |
NCT06155279 | Phase II | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab | Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA) | Recruiting | ITA | 0 |
NCT06255665 | Phase I | JNJ-79032421 | A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Recruiting | ESP | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06477419 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan in People With Mesothelioma | Recruiting | USA | 0 |